跳转至内容
Merck
CN

SML0201

SB 297006

别名:

N-Benzoyl-4-nitro-L-phenylalanine ethyl ester

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C18H18N2O5
化学文摘社编号:
分子量:
342.35
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C18H18N2O5/c1-2-25-18(22)16(19-17(21)14-6-4-3-5-7-14)12-13-8-10-15(11-9-13)20(23)24/h3-11,16H,2,12H2,1H3,(H,19,21)/t16-/m0/s1

SMILES string

CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c2ccccc2

InChI key

BEZXGSZPWXRHIN-INIZCTEOSA-N

optical activity

[α]/D -60 to -78° in ethanol (c=1)

color

white to tan

solubility

DMSO: ≥15 mg/mL

storage temp.

2-8°C

Application

SB 297006 may be used to study CCR3-mediated cell signaling in asthma models.

Biochem/physiol Actions

CCR3 Antagonist
SB 297006 inhibits the recruitment and migration of eosinophils in allergen models of models. It suppresses the Th2-mediated eosinophil infiltration in the airways.
SB-297006 is a potent, selective CCR-3 antagonist (IC50 = 60 nM). The compound blocked CCR3 agonist-induced calcium mobilization in CCR3 expressing cells with the following IC50 values: eotaxin, 210 nM; eotaxin-2, 90 nM and MCP4, 80 nM.

Features and Benefits

This compound is featured on the Chemokine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

Exclamation markEnvironment

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Peter J Barnes
Annual review of pharmacology and toxicology, 42, 81-98 (2002-01-25)
Cytokines play a critical role in orchestrating and perpetuating inflammation in asthmatic airways and several specific cytokine and chemokine inhibitors are now in development for the treatment of asthma. Inhibition of IL-4 with soluble IL-4 receptors has shown promising early
Leyi Gong et al.
Expert opinion on therapeutic patents, 19(8), 1109-1132 (2009-07-30)
Since the mid-1990s, there has been significant effort invested in the discovery and clinical development of CC chemokine receptor-3 (CCR3) antagonists as potential therapeutics for airway disease. A patent literature review is presented of small molecule CCR3 antagonists comprising the

商品

We offer many products related to chemokine receptors for your research needs.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持